A comprehensive view of Merck KGaA. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Tissue & Hygiene Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Merck KGaA hands over IL-12-targeting cancer drug to PDS Biotech in deal worth over US$120.0M; the two companies are currently developing a triple combination immunotherapy to treat HPV-associated malignancies
Published: January 04, 2023 by FierceBiotech
Amgen, Merck KGaA sign separate deals to develop cancer-targeting antibody-drug conjugates with external drug developers in deals worth up to US$2.0B; Amgen partners with LegoChem Biosciences, Merck partners with Mersana Therapeutics
Published: December 28, 2022 by FierceBiotech
CEOs of BioNTech, Bayer, Merck KGaA join German Chancellor Scholz in high-profile China visit
Published: November 30, 2022 by Indian Pharma Industry: Policies
Merck KGaA plans to double R&D productivity, introduce one new product or major indication every 1.5 years on average; over 50% of new launches to result from external co-development partnerships and strategic in-licensing of assets
Published: November 22, 2022 by Business Wire
AstraZeneca and MSD's Lynparza combined with abiraterone and prednisone or prednisolone has been recommended in the EU for approval as a treatment for metastatic castration-resistant prostate cancer
Published: November 14, 2022 by AstraZeneca AB

Ask us about our Tissue & Hygiene market view

Trending Chart

Interactive chart with headline count